'My left breast was moved to my right after cancer recurred'
Five months into a pregnancy for a much wanted second child in 2024, Nicola Purdie found a lump in her right breast.
It is a nightmare scenario for anyone. But for Nicola this was not a new experience.
She had already had a double mastectomy, chemotherapy and breast reconstruction after being diagnosed with cancer in 2020.
But a radical idea which she suggested to her surgeon has led to what is believed to be a pioneering world first procedure - transplanting a healthy reconstructed breast to replace a cancerous one.
In September 2020, Nicola had just finished with breastfeeding her first child and was returning to work as a geography teacher in her home town of Swansea when she found a lump.
By October it was diagnosed as cancer and she started five months of chemotherapy at Singleton Hospital, followed by the double mastectomy.
Nicola, now 38, said: "Even though I only had cancer in the one breast, my maternal aunty and maternal grandmother also had had breast cancer previously. I thought 'I'm young, let's just get rid of everything and do as much as we can'."
She had reconstructive surgery using skin and tissue from her abdomen in a procedure known as a DIEP (deep inferior epigastric perforator) flap.
"It meant I had natural breasts which would grow and shrink with my bodyweight over time and I wouldn't need implants that would need changing in 10 or 15 years," she said.
Because the cancer was oestrogen-fuelled, she was placed on hormone suppression therapy for at least two years.
"We knew at the time I was diagnosed that we wanted to have another baby eventually, so we waited for two-and-a-half years actually.
"All the oncologists we saw were of the same opinion that I was at no increased risk, because I'd had a complete pathological response [no sign of cancer post-treatment]."
Then lump number two appeared.
Nicola explained: "This time it was in the skin of the breast because that was the only tissue that was remaining really from the first surgery. There must have been some cancer cells there.
"I knew straight away as soon as I found the lump, this is not a coincidence. This is cancer again."
Apart from family and a close friend, Nicola did not tell anyone about the cancer this time. Partly it was to shield her daughter from knowing but she had another reason.
"I wanted to protect the baby. I wanted him to come into the world and it to be all about him. I didn't want it to be focusing on 'oh gosh Nicky, you OK?'."
She attributes this mindset to helping her "shut the door" on thinking about it until her son was born.
Because of pregnancy, she could not begin chemotherapy, or have the usual scans to establish if the cancer had spread.
She had some chest X-rays and an ultrasound of her stomach and liver, which gave a degree of certainty, although not "100%", that it remained contained in the breast.
She also had a lumpectomy to remove the lump from the breast skin.
The plan was to deliver the baby at 32 weeks, at the end of August, but even in the midst of the urgency for treatment, she had an eye to her son's future.
"I think it was 26 August and I said 'can I put my teacher's hat on now and push it to the week after'.
"My husband was like 'what?' But I said 'I've got to give him the best chance'.
"So we waited until the first Monday in September and he was born at 32 weeks and six days."
Fraser was in the neonatal unit for three weeks. "He went from strength to strength and that made things easier as well because of what I was dealing with.
"I don't know how I would have been if he was poorly as well."
Nicola started chemotherapy two weeks after giving birth and would go from the baby unit upstairs to have her treatment and then straight back down to her son.
She had 16 rounds of chemo which took her all the way through to the beginning of February.
Woman has pioneering breast reconstruction surgery
'Reconstructive breast surgery wait just adds to the ordeal'
The cancer survivors waiting years for breast reconstruction
Initially the oncology team had not been sure what operation to suggest as Nicola had multiple cancer sites in the right breast area and a tumour in one lymph node.
The most likely option was removal and an LD (latissimus dorsi) flap, which involves swinging a muscle and skin from the back to cover the area left behind by the removed breast, but leaving the area flat in her case.
Reconstruction using an implant on the right side instead would not have been possible as so much skin had to be removed, there would not be enough to cover it, or to withstand damage from subsequent radiation treatment.
However, Nicola's aunt had had the LD flap operation and she knew it came with an arduous recovery process and possibly reduced range of movement - not an option for her as the mother of two small children.
She also knew she wanted "symmetry" - either two breasts or none.
It was while talking to her sisters she initially had the idea that, if she did end up having both breasts removed, why not use the skin from the healthy left breast to cover the larger affected area on the right.
But it was only once she was in the consulting room with consultant plastic, reconstructive and breast surgeon Reza Arya, that the idea of moving the whole breast intact dawned.
She realised it would allow her to create a right breast and have reconstructive surgery on the left side using an implant because there was enough skin left in situ from the first operation in 2020.
When she put this to Reza - "could we rob Peter to pay Paul?" - she "could literally see the cogs whirring" in his head.
He recalled being speechless at the idea.
"I had never seen or heard of such a procedure being talked about or published.
"I wasn't even sure at that stage whether I would be adding to Nicola's care or taking away from it."
Reza said it was very unusual to have a patient come up with such a radical idea.
"Kudos to Nicola because she's amazing.
"I had extensive discussions with colleagues all over the UK who are all experts in flap reconstruction from the abdomen. The conclusion was maybe it is possible and just go ahead with it.
"This is not run of the mill mastectomy we're talking about," he said.
"We're removing the whole of the footprint of the breast [on the right]. It is a very, very large area of skin and to be able to close it you have to borrow from somewhere, some skin and tissue, that can withstand future radiotherapy.
"Left is a side that's easy to reconstruct in future, because it's not subject to radiotherapy and all other treatments, and the cancer itself."
When Nicola went into the surgery, she knew she could wake up to very different outcomes - a successful left to right transplant, or an LD flap reconstruction on her right side after all if he decided the transfer would not work, with the left breast removed anyway at her request.
She gave Reza her blessing for any outcome. And her outrageous gamble paid off.
"What makes it a world first is that the tissue has been ported to two different sites," she said.
"We didn't know if that would be possible or probable, the microsurgery of actually sewing the vessels together - if it would work or if it would be so scarred that it would be completely impossible."
She is starting a few weeks of radiotherapy, and around Christmas time will have reconstructive surgery on the left side using a saline implant.
She will be on hormone therapy for the next 10 years to manage the risks of recurrence but has been given the all-clear in terms of this treatment cycle.
For someone who has been through such gruelling experiences, she is remarkably upbeat. How does she stay positive?
"If I am having those moments when I feel 'oh my god this is awful, why has this happened to us?'
"I let myself think about it for a minute and then move on to the next thing. If you don't allow yourself to think about it, it won't get you down.
"I have to sit back and think 'this is life. Worse things can happen'. I'm lucky that I've had incredible treatment from the word go, and an amazing team who I trust."
She added: "Both the kids were just the best distraction ever. It's hope isn't it? When you see little children. You think there's hope for the future."
Amy Dowden reflects on life after cancer treatment
'Breast cancer is more than surgery and chemo'
Woman's breast reconstruction delayed three times
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
GPs receive new training to help endometriosis diagnosis
GPs are receiving new training to help improve early diagnosis. The scheme focuses on endometriosis, a condition affecting one in 10 women in Wales, and is part of the Welsh Government's Women's Health Plan, launched six months ago. The expert-led programme is delivered by Health Education and Improvement Wales (HEIW) and has already led to a 43 per cent increase in GP knowledge about endometriosis, boosting confidence in discussing symptoms and treatment options. Sarah Murphy, minister for mental health and wellbeing, said: "Women have told us that they feel they are not heard, and their symptoms are ignored. "This training ensures women's voices are central to their healthcare experience, and it helps GPs support their patients more effectively. "Endometriosis can have a huge impact on a woman's quality of life, their work and their relationships. "I am determined our Women's Health Plan will drive real improvements in women's health outcomes and reduce inequalities." Dr Mirka Slavska, an obstetrics and gynaecology consultant at Aneurin Bevan University Health Board who delivered the training, said: "I was delighted to deliver this training with Health Education and Improvement Wales. "The session covered differential diagnoses, referral pathways, novel diagnostic and treatment options, and introduced the Endometriosis Cymru symptom reporting tool. "The excellent feedback we received reflects the value of equipping healthcare professionals with current, practical knowledge to improve care for those living with endometriosis." Endometriosis is one of eight priority areas in the Women's Health Plan, published in December. Since its launch, key achievements include plans for a women's health hub in every health board area by March 2026, the creation of Wales' first women's health research centre, and a focused call for research into women's health communication. Dr Helen Munro, clinical lead for Women's Health in Wales, provided an update on the health hubs at the Everywoman Festival in Cardiff. She said: "Meeting women's needs across their life course will be at the heart of the new women's health hubs. "This is where healthcare professionals will join up with existing services to provide women's health services within our communities."
Yahoo
2 hours ago
- Yahoo
Doctors try 'poo pills' to flush out dangerous superbugs
UK doctors are attempting to clear dangerous superbug infections using "poo pills" containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data suggests superbugs can be flushed out of the dark murky depths of the bowel and replaced with a mix of healthy gut bacteria. It is a new approach to tackling infections that resist antibiotics, which are thought to kill a million people each year. The focus is on the bowels which are "the biggest reservoir of antibiotic resistance in humans" says Dr Blair Merrick, who has been testing the pills at Guys and St Thomas' hospitals. Drug-resistant superbugs can escape their intestinal home and cause trouble elsewhere in the body – such as urinary tract or bloodstream infections. "So there's a lot of interest in 'can you get rid of them from the gut?'," says Dr Merrick. The idea of poo-pills isn't as far-fetched as it might seem. Faecal transplants – also known as a trans-poo-tion - are already approved for treating severe diarrhoea caused by Clostridium difficile bacteria. But scientists noticed hints that faecal transplants for C. difficile also seemed to get rid of superbugs. Microbiome podcast: Manipulating Our Hidden Half New research has focused on patients who had an infection caused by drug-resistant bacteria in the past six months. They were given pills made from faeces which people had donated to a stool bank. Each stool sample is tested to ensure it does not contain any harmful bugs, undigested food is removed and then it is freeze dried into a powder. This is stored inside a pill that can pass through the stomach unscathed and reach the intestines where it dissolves to release its poopy powdery payload. The trial has taken place on 41 patients at Guy's and St Thomas' hospitals in London to lay the groundwork for a large-scale study. It showed patients were up for taking a poo pill and the donated bacteria were still being detected in the bowels at least a month later. Dr Merrick says there are "really promising signals" that poo pills could help tackle the rising scourge of superbugs and that donor bacteria could be going to microbial war with the superbugs as they compete over food and space on the lining of the gut and either rid the body of them completely or "reduce them down to a level that doesn't cause problems". The study also suggests the array of gut bacteria becomes more varied after the therapy. This is a sign of good health and "may well be promoting colonisation resistance" so it is harder for new infectious bugs to get in. "It's very exciting. There's a real shift from 20 years ago where all bacteria and viruses were assumed to do you harm; to now where we realise they are completely necessary to our overall health," says Dr Merrick. Earlier this week scientists showed the good bacteria our bodies meet – in the hours after we are born – seem to halve the risk of young children being admitted to hospital with lung infections. First bacteria we ever meet can keep us out of hospital More than half your body is not human Our body's own human cells are outnumbered by the bacteria, fungi and others that live inside us - known as the microbiome. This has led to research implicating the microbiome in everything from Crohn's disease to cancer to mental health. If poo pills are proven to work against superbugs in larger studies then the researchers think they could be used for both treatment and prevention in people at risk. Medical procedures that suppress the immune system - including cancer therapies and organ transplants - can make the body more vulnerable. "A lot of these individuals come to a lot of harm from drug resistant organisms," Dr Merrick. The UK's drugs regulator – the Medicines and Healthcare Products Agency – said there were more than 450 microbiome medicines currently in development. "Some of them will success, so I do think we will seem them coming through quite soon," said Dr Chrysi Sergaki, the head of microbiome research at the MHRA. "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."